Amorphous Solid Dispersion Composition for Stable Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for stable bioavailable pharmaceutical compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide to treat cystic fibrosis, particularly for patients with mutations like ΔF508-CFTR, as current treatments do not effectively address the reduced anion transport and mucus accumulation caused by defective CFTR protein folding and trafficking.
Innovation Solution
The development of a solid dispersion of amorphous N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, combined with polymers like HPMCAS or PVP/VA, and optional excipients such as fillers, disintegrants, surfactants, and lubricants, to enhance stability and bioavailability, formulated into tablets with specific dissolution and hardness properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the compound is formulated in a crystalline form, then the manufacturing stability is improved, but the bioavailability and dissolution rate deteriorate
Solution Approach 1:
The patent transforms the compound from a crystalline state to an amorphous state, fundamentally changing the physical parameter of molecular arrangement. This parameter change eliminates the ordered crystal lattice structure that causes slow dissolution, while the amorphous form provides superior bioavailability. The amorphous formulation maintains stability through proper formulation techniques rather than relying on crystal lattice energy.
Solution Approach 2:
The patent creates a composite formulation by combining the amorphous compound with excipients and carriers. This composite approach allows the amorphous compound to maintain its dissolution advantages while the formulation system as a whole provides the necessary stability for storage and handling. The composite material strategy enables both contradictory requirements to be satisfied simultaneously.
2Ease of operation
If the compound is administered orally, then the ease of operation is improved, but the bioavailability deteriorates due to poor solubility
Solution Approach 1:
The patent changes the physical state parameter from crystalline to amorphous, which fundamentally alters the dissolution behavior. The amorphous form has higher free energy and lacks the ordered structure that impedes solubility, thereby improving bioavailability while maintaining the convenient oral administration route.
Solution Approach 2:
The patent introduces excipients and formulation components as intermediaries that facilitate the dissolution and absorption of the amorphous compound. These mediators help bridge the gap between the hydrophobic compound and the aqueous gastrointestinal environment, enabling reliable bioavailability through oral administration.
3Reliability
If the compound is formulated with high purity, then the therapeutic efficacy is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent changes the physical state to amorphous, which inherently provides better dissolution and bioavailability, thereby improving therapeutic efficacy. The amorphous formulation process, while requiring careful control, can be achieved through established techniques like spray drying or melt extrusion, balancing purity requirements with manufacturing feasibility.
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.